Cronos Group (CRON) Q3 2026 earnings review

New Greenhouse Supply Lifted Flower Sales 82%

Cronos spent last year expanding Cronos GrowCo, its majority-owned cultivation joint venture in Ontario, to fix a shortage of dried cannabis flower. That added greenhouse space is now supplying both domestic and export markets. Chief executive Mike Gorenstein said that "Cronos organically achieved records across net revenue, gross profit, and Adjusted EBITDA for the second consecutive quarter, while at the same time reducing shares outstanding."

• Cannabis flower net revenue: $48.0 million, up 82% from a year ago (78% in constant currency)
• Cannabis extracts net revenue: $15.5 million, up 55% from a year ago
• Total net revenue: $63.5 million, up 75% from a year ago (73% in constant currency)

The jump in flower sales proves that limited supply, rather than weak consumer demand, held the cannabis producer back in 2025. Yet the third quarter of last year was an unusually easy comparison because delayed overseas shipments held year-ago growth to 6%. What to watch: fourth-quarter revenue growth excluding the new Dutch acquisition. A strong reading against last year's tougher fourth quarter would show that demand can grow even after the greenhouse expansion turns one year old.

Spinach Keeps Taking Canadian Retail Share

Spinach is the company's main adult-use cannabis brand in Canada, selling gummies, vape pens, dried flower, and pre-rolled joints. While the wider Canadian retail cannabis market grew 1% from a year ago, retail sales of Spinach products rose 41%, lifting its national market share to 6.3% from 5.9% last quarter.

New flavours in its SOURZ gummy line and PUFFERZ all-in-one disposable vapes kept the brand in first place nationwide across both edibles (21.8% share) and vapes (11.4% share). What to watch: the gap between Cronos's 52% Canadian wholesale revenue growth and its 41% retail sales growth next quarter. A narrowing gap would show that provincial distributors are selling the extra inventory rather than just stocking shelves.

German Demand and Dutch Deal Expand Europe

Cronos sells medical cannabis overseas under its PEACE NATURALS brand and seeks European growth because those exports carry no Canadian excise taxes. In the third quarter, net revenue outside Canada and Israel reached a record $13.2 million, up 614% from $1.9 million a year ago, led by flower shipments to Germany. Two weeks after the quarter ended, on October 15, the Toronto-based group "completed the acquisition of CanAdelaar B.V.", the largest grower in the Netherlands' legal adult-use pilot programme.

Closing the Dutch deal ends months of regulatory delays and gives the business "a leadership position in Europe’s largest adult-use cannabis market", Gorenstein said. Because international shipments carry higher average prices and no excise taxes, they accounted for 44.6% of total net revenue this quarter by our math, supporting profits. What to watch: CanAdelaar's first standalone revenue contribution in the fourth-quarter report, which will show how much immediate scale the Dutch market adds.

Operating Profit Swung Positive as Overhead Shrank

Rising sales volume and a shift toward "higher cannabis flower sales in Israel and other countries, specifically Germany, which carry no excise taxes" lifted gross margin by 0.5 percentage points from a year ago to 50.9%. Although gross margin stepped down from last quarter's seasonal peak of 53.7%, operating income reached $9.0 million against an operating loss of $0.5 million a year ago because day-to-day overhead grew much slower than revenue.

General and administrative expenses (corporate overhead and legal fees) fell by 6.6 percentage points of revenue to 18.9% by our math, while sales and marketing dropped 3.3 percentage points to 11.2%. Cronos also spent $9.4 million to buy back 3.2 million shares, though that pace slowed from $16.1 million last quarter. What to watch: fourth-quarter gross margin, as winter harvests typically test whether the company can hold margins near 50%.